Highlights From the 15th Annual Congress of EAHAD
Dose Selection and Study Design for B-LIEVE, A Phase 1/2 Dose Confirmation Clinical Trial of FLT180A Gene Therapy for Patients with Hemophilia B
G.Young1,P.Chowdary, 2,3,S.Barton4, A.Long4
1Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, United States;2 Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital;3 University College London,United Kingdom;4 Freeline, Stevenage, United Kingdom
RELATED CONTENT
Interactive Webinars
Long-term Outcomes: Durability and Safety
Presented by Prof. Margareth C. Ozelo, MD, PhD...
Obstacles and Opportunities
Presented by Frank W.G. Leebeek, MD, PhD...
Patient Support, Patient Counseling, and Monitoring
Presented by Lindsey A. George, MD...
Gene Therapy for FVIII
Presented by K. John Pasi, MB ChB, PhD, FRCP, FRCPath, FRCPC...
Update on Efficacy of Clinical Trials
Presented by Guy Young, MD...
Adeno-Associated Viral (AAV) Vector Gene Therapy: Application to Hemophilia
Presented by Barbara A. Konkle, MD...
Gene Therapy for Treatment of Hemophilia: An Introduction to Adeno-Associated Viral Vector Gene Transfer
Presented by Johnny Mahlangu, BSc, MBBCh, MMed, FCPath...
Gene Therapy for Treatment of Hemophilia: Common Concerns in Gene Therapy
Presented by Thierry VandenDriessche, PhD...
Gene Therapy for Treatment of Hemophilia: Other Strategies and Targets
Presented by Glenn F. Pierce, MD, PhD...
A History of Hemophilia Treatment: Non-replacement Therapy to Gene Therapy
Presented by Steven W. Pipe, MD...
Getting to Know Gene Therapy: Terminology and Concepts
Presented by David Lillicrap, MD...
A History of Hemophilia Treatment: Factor Replacement to Gene Therapy
Presented by Flora Peyvandi, MD, PhD...
Podcasts